Skip to Main Content
Contribute Try STAT+ Today

Amid increasing debate over the cost of prescription drugs, a federal watchdog agency found the National Institutes of Health does not consider whether a medicine it discovered and licensed to a pharmaceutical company may later be affordable, and also fails to provide enough information about its licensing activities to assess patient access.

The failure to consider the impact that licensing has on public health, especially at a time when a growing number of Americans say they cannot afford their medicines, prompted the Government Accountability Office to recommend that the NIH do a better job of disclosing licensing data and pay more attention to the potential for anti-competitive practices that affect drug pricing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Mr Silverman , Thank you for your article . I do have a few questions about NIH and it’s licensing practices. In your research did you discover any way that the taxpayer gets reimbursed as deposits to the US Treasury from the license holder for the drugs that have been developed by the people at NIH?
    Do the people who developed these Drugs while working for NIH get to file patents in their name for the drugs they developed while working for the taxpayers ? Thanks for your time ,
    Mark Fitzsimmons

Comments are closed.